Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
July 22, 2024 12:04 PM EDT
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $33.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).
The analyst comments "Ahead of the 2024 Angelman Syndrome Foundation conference, IONS reported six-month Ph1/2 data on antisense oligonucleotide (ASO) ION582 in Angelman syndrome (n=11, 13 and 27 at the low, medium and high doses), where 67% of medium/high-dose patients improved vs. natural history,... More
July 22, 2024 7:03 AM EDT
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS) demonstrating consistent and encouraging clinical improvement on measures assessing all functional domains including communication, cognition and motor function. Overall, 97% of people in the medium and high dose... More
